Related Experiment Videos
Identical variant TSG101 transcripts in soft tissue sarcomas and various non-neoplastic tissues
Molecular Carcinogenesis
|December 30, 1998
Summary
Altered TSG101 gene expression, initially linked to cancer, was investigated in soft-tissue sarcomas. Aberrant transcripts were found in both tumors and normal tissues, suggesting splicing issues, not cancer-specific mutations.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- The TSG101 gene's role in malignant transformation and potential tumor suppression has been debated.
- Previous studies suggested TSG101 alterations in human cancers, but findings were inconsistent.
Purpose of the Study:
- To investigate TSG101 gene transcription patterns in soft-tissue sarcomas and non-neoplastic human tissues.
- To determine if aberrant TSG101 expression contributes to soft-tissue sarcoma development.
Main Methods:
- Analysis of TSG101 transcription patterns in 71 soft-tissue sarcoma and 15 non-neoplastic samples.
- Restriction fragment length polymorphism (RFLP) analysis to detect genomic rearrangements.
- Northern blot analysis to quantify transcript abundance.
Main Results:
- Aberrant TSG101 transcripts were detected in 63% of soft-tissue sarcomas and also in 47% of non-neoplastic control tissues.
- RFLP analysis ruled out major genomic rearrangements in sarcoma samples.
- Variant TSG101 transcripts were present at very low levels compared to wild-type transcripts.
Conclusions:
- The observed aberrant TSG101 transcripts are likely due to aberrant mRNA splicing in both normal and transformed human mesenchymal tissues.
- The study does not support a pathogenic role for altered TSG101 expression in human soft-tissue sarcomas.